Using our revolutionary KnotBody® technology, we are creating first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases.
It affects ~1.5 billion people worldwide and ~64% of patients on the current pain medications are inadequately treated.
More than 300 million people worldwide suffer from autoimmune disorders.
Cardiovascular disease is the leading cause of death globally.
Ion channel and GPCR disfunction are implicated in a wide range of debilitating diseases and current treatments based on small molecule drugs suffer from poor efficacy and side effects.
Compared to small molecules, engineered antibodies offer vastly superior selectivity and are well proven therapeutically, representing 7/10 of top-selling drugs.
Despite these obvious advantages, antibody discovery against ion channel and GPCRs has been challenging.
By fusing naturally occurring cysteine-rich miniproteins (‘Knottins’) into antibody binding loops, our patented KnotBody® technology combines the power of millions of years of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques, addressing key challenges in ion channel and GPCR drug discovery.
Potency and Selectivity
Half-life & Manufacturability
Potency & Selectivity
Half-life & manufacturability
We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets.
John McCafferty, PhD
Co-founder and CEORead more
Prior to co-founding Maxion Therapeutics, John was a co-founder of Cambridge Antibody Technology (acquired by AstraZeneca) and IONTAS (acquired by FairJourney Biologics). John was an inventor of antibody phage display technology which earned the 2018 Nobel prize in chemistry (awarded to his co-inventor Sir Greg Winter). He also invented IONTAS’s proprietary Mammalian Display technology as well as Maxion’s KnotBody® technology.
Aneesh Karatt-Vellatt, PhD
Co-founder and CSORead more
Ian Tomlinson, PhD
Thomas Weaver, PhD
Non-executive DirectorRead more
Babraham Research Campus
Cambridge CB22 3AT